MEDILET ApS - CVR: 32891470

2022, DKK

26.07.2023

Bruttoresultat

-333'

Primær drift

-333'

Årets resultat

-260'

Aktiver

13.075'

Kortfristede aktiver

574

Egenkapital

-390'

Afkastningsgrad

-3 %

Soliditetsgrad

-3 %

Likviditetsgrad

0 %

Resultat

26.07.2023

Årsrapport	2022 26.07.2023	2021 24.06.2022	2020 09.07.2021	2019 15.05.2020	2018 03.06.2019	2017 01.06.2018	2016 09.06.2017	2015 01.06.2016
Nettoomsætning
Bruttoresultat	-332.517	-21.919	-23.513	-28.306	-24.025	-28.288	-25.912	-43.200
Resultat af primær drift	-332.517	-21.919	-23.513	-28.306	-24.025	-28.288	-25.912	-43.200
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0	0
Finansielle indtægter	0	0	0	0	0	0	0	0
Finansieringsomkostninger	-645	0	0	0	0	0	0	0
Andre finansielle omkostninger	0	0	0	0	0	0	0	0
Resultat før skat	-333.162	-21.919	-23.513	-28.306	-24.025	-28.288	-25.912	-43.200
Resultat	-259.942	-17.097	-18.327	-15.866	-25.229	-88.407	46.132	80.566
Forslag til udbytte	0	0	0	0	0	0	0	0

Aktiver

26.07.2023

Årsrapport	2022 26.07.2023	2021 24.06.2022	2020 09.07.2021	2019 15.05.2020	2018 03.06.2019	2017 01.06.2018	2016 09.06.2017	2015 01.06.2016
Kortfristede varebeholdninger	0	0	0	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	160	5.032	29.176	57.938	670.654	636.678	837.501	1.097.492
Likvider	414	1.618	3.778	78.584	5.845	2.898	3.288	3.185
Kortfristede aktiver	574	6.650	32.954	136.522	676.499	639.576	840.789	1.100.677
Immaterielle aktiver og goodwill	13.074.480	13.074.480	13.056.721	12.899.429	12.569.162	11.636.703	9.708.741	7.617.752
Finansielle anlægsaktiver	0	0	0	0	0	0	0	0
Materielle aktiver	0	0	0	0	0	0	0	0
Langfristede aktiver	13.074.480	13.074.480	13.056.721	12.899.429	12.569.162	11.636.703	9.708.741	7.617.752
Aktiver	13.075.054	13.081.130	13.089.675	13.035.951	13.245.661	12.276.279	10.549.530	8.718.429

Aktiver

26.07.2023

Passiver

26.07.2023

Årsrapport	2022 26.07.2023	2021 24.06.2022	2020 09.07.2021	2019 15.05.2020	2018 03.06.2019	2017 01.06.2018	2016 09.06.2017	2015 01.06.2016
Forslag til udbytte	0	0	0	0	0	0	0	0
Egenkapital	-390.206	-130.264	-113.167	-94.840	-78.974	-53.746	34.662	-11.470
Hensatte forpligtelser	2.565.762	2.638.982	2.639.897	2.640.207	2.608.734	2.464.284	1.980.014	1.592.040
Langfristet gæld til banker	0	0	0	0	0	0	0	0
Anden langfristet gæld	0	0	0	0	0	0	0	0
Leverandører af varer og tjenesteydelser	2.891.258	2.893.758	2.898.070	2.773.359	2.776.391	2.267.584	1.626.841	1.308.150
Kortfristede forpligtelser	10.899.498	10.572.412	10.562.945	10.490.584	10.715.901	9.865.741	8.534.854	7.137.859
Gældsforpligtelser	10.899.498	10.572.412	10.562.945	10.490.584	10.715.901	9.865.741	8.534.854	7.137.859
Forpligtelser	10.899.498	10.572.412	10.562.945	10.490.584	10.715.901	9.865.741	8.534.854	7.137.859
Passiver	13.075.054	13.081.130	13.089.675	13.035.951	13.245.661	12.276.279	10.549.530	8.718.429

Passiver

26.07.2023

Nøgletal

26.07.2023

Årsrapport	2022 26.07.2023	2021 24.06.2022	2020 09.07.2021	2019 15.05.2020	2018 03.06.2019	2017 01.06.2018	2016 09.06.2017	2015 01.06.2016
Afkastningsgrad	-2,5 %	-0,2 %	-0,2 %	-0,2 %	-0,2 %	-0,2 %	-0,2 %	-0,5 %
Dækningsgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	66,6 %	13,1 %	16,2 %	16,7 %	31,9 %	164,5 %	133,1 %	-702,4 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-51.553,0 %	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Soliditestgrad	-3,0 %	-1,0 %	-0,9 %	-0,7 %	-0,6 %	-0,4 %	0,3 %	-0,1 %
Likviditetsgrad	0,0 %	0,1 %	0,3 %	1,3 %	6,3 %	6,5 %	9,9 %	15,4 %

Resultat

26.07.2023

Gæld

26.07.2023

Årsrapport

26.07.2023

Nyeste:01.01.2022- 31.12.2022(offentliggjort: 26.07.2023)

Information om virksomhedens regnskabsklasse:The annual report for Medilet ApS has been presented in accordance with the Danish Financial Statements Act regulations concerning reporting class B enterprises. Furthermore, the company has decided to comply with certain rules applying to reporting class C enterprises. The accounting policies are unchanged from last year, and the annual report is presented in DKK.

Beretning

26.07.2023

Dato for ledelsens godkendelse af årsrapporten:2023-07-21

Beskrivelse af usikkerhed ved indregning eller måling:Uncertainties about recognition or measurement Medilet is a R&D company and therefore with a built-in uncertainty about recognition and measuring of the actual and activated patent and R&D costs. All costs incurred will be carried at cost. The real value of assets for the company is not known until the company’s products are closer to be finalized and ready for marketing.

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the managing director has presented the annual report of Medilet ApS for the financial year 1 January - 31 December 2022.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:The principal activities of the company The principal activities of Medilet ApS are a medical device company with a focus on the formulation and development of medical device products. Medilet ApS concentrates on research and development and manufacturing, aiming at products and processes that are patentable and have a broad appeal. The Company has today developed its first medical device system, a novel dual chamber syringe, a unique technology that during the development period will further improve the technology with more features compared to the dual chamber syringe products on the market. So, compared to the leading existing technology, this technology offers unique benefits breaking new ground especially for home care patients with a unusual simple and extremely safe technology. The market for dual chamber syringes is dominated by one company in a market growing extremely fast to reach >$3. 3 billion in few years. The business strategy is to be able alone or with a co-developer to control most aspects of the drug development efforts from product formulation to clinical testing, regulatory submissions, and manufacturing. Consequently, Medilet will increasingly focus its resources on a range of medical device products securing licensing agreements with major pharmaceutical companies securing significant royalty and product revenues.